N-(3-tert-butylphenyl)benzamide | 1365655-96-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-tert-butylphenyl)benzamide
• CAS: 1365655-96-4
• 化学式: C₁₇H₁₉NO
• 分子量: 253.344
• InChiKey: DIQSHLNGLWOXOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(3-tert-butylphenyl)benzamide 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 8.17h， 生成 N-benzyl-N'-(3-tert-butylphenyl)benzimidamide
  参考文献：
  名称：

  Solvent/Oxidant-Switchable Synthesis of Multisubstituted Quinazolines and Benzimidazoles via Metal-Free Selective Oxidative Annulation of Arylamidines

  摘要：

  A fast and simple divergent synthesis of multisubstituted quinazolines and benzimidazoles was developed from readily available amidines, via iodine(III)-promoted oxidative C(sp(3))-C(sp(2)) and C(sp(2))-N bond formation in nonpolar and polar solvents, respectively. Further selective synthesis of quinazolines in polar solvent was realized by TEMPO-catalyzed sp(3)C-H/sp(2)C-H direct coupling of the amidine with K2S2O8 as the oxidant. No metal, base, or other additives were needed.

  DOI：

  10.1021/ol500864r
• 作为产物：
  描述：

  N-(3-乙酰苯基)苯甲酰胺 在 氯化亚砜 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 、 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成 N-(3-tert-butylphenyl)benzamide
  参考文献：
  名称：

  Access to “Friedel–Crafts-Restricted” tert-Alkyl Aromatics by Activation/Methylation of Tertiary Benzylic Alcohols

  摘要：

  Herein we describe a two-step protocol to prepare m-tert-alkylbenzenes. The appropriate tertiary benzylic alcohols are activated with SOCl2 or concentrated HCl and then treated with trimethylaluminum, affording the desired products in 68-97% yields (22 examples). This reaction sequence is successful in the presence of a variety of functional groups, including acid-sensitive and Lewis-basic groups. In addition to t-Bu groups, 1,1-dimethylpropyl and 1-ethyl-1-methylpropyl groups can also be installed using this method.

  DOI：

  10.1021/jo202371c

文献信息

• 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
  申请人：Djung Far-Jine Jane

  公开号：US20070293494A1

  公开（公告）日：2007-12-20

  The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.

  本发明涉及2-芳基氨基-4-(杂环)氨基嘧啶抑制剂，这些抑制剂是蛋白激酶C-alpha (PKC-α)的抑制剂，因此能够抑制PKC-α。本发明的PKC-α抑制剂对于改善心肌细胞内钙循环非常重要，从而提高心肌的收缩和舒张性能，从而减缓心力衰竭的进展。本发明还涉及包含所述2-芳基氨基-4-(杂环)氨基嘧啶的组合物以及用于控制、减轻或以其他方式减缓心力衰竭进展的方法。
• Triflic anhydride mediated synthesis of 3,4-dihydroquinazolines: a three-component one-pot tandem procedure
  作者：Christina L. Magyar、Tyler J. Wall、Steven B. Davies、Molly V. Campbell、Haven A. Barna、Sydney R. Smith、Christopher J. Savich、R. Adam Mosey

  DOI：10.1039/c9ob01596e

  日期：——

  A one-pot three-component tandem reaction involving a key Pictet-Spengler-like annulation step has been developed, providing an efficient method for the synthesis of 3,4-dihydroquinazolines in moderate to good yields from amides, aldehydes, and amines. The multicomponent triflic anhydride mediated reaction tolerates the installation of numerous functional groups, affording extensive diversity about

  已经开发了涉及关键的Pictet-Spengler样环化步骤的一锅三组分串联反应，为从酰胺，醛和胺中到高收率的合成3,4-二氢喹唑啉提供了一种有效的方法。多组分三氟甲磺酸酐介导的反应可耐受许多官能团的安装，从而为杂环支架提供了广泛的多样性。
• ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANER DRUGS
  申请人：National Taiwan University

  公开号：US20140080848A1

  公开（公告）日：2014-03-20

  A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.

  基于厄洛替尼（一种EGFR抑制剂）骨架合成了一系列单取代和双取代的喹唑啉和嘧啶衍生物，并评估了它们对肝细胞癌和人类肺腺癌的生物活性。
• 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES
  申请人：DJUNG Jane Far-Jine

  公开号：US20090227586A1

  公开（公告）日：2009-09-10

  The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.

  本发明涉及2-芳基氨基-4-(杂环)氨基嘧啶抑制剂，它们是抑制剂，因此可以抑制蛋白激酶C-alpha (PKC-α)。本发明的PKC-α抑制剂对于改善心肌细胞内钙循环非常重要，从而改善心肌收缩和松弛性能，从而减缓心力衰竭的进展。本发明还涉及包含所述2-芳基氨基-4-(杂环)氨基嘧啶的组合物以及用于控制、减轻或减缓心力衰竭进展的方法。
• Oxadiazole Derivative as Dgat Inhibitors
  申请人：Birch Martin Alan

  公开号：US20080096874A1

  公开（公告）日：2008-04-24

  Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.

  式（I）的化合物，以及其盐和前药：其中，例如R1是可选取代芳基或杂环芳基；Y是选择自直接键和（取代）烷基链等的连接基；R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。还描述了制备此类化合物的方法及其作为DGAT抑制剂的用途，例如在肥胖症的治疗中。